March 28 (Reuters) - Bristol Myers Squibb ( BMY ) said
on Thursday its experimental drug to treat Crohn's disease, a
chronic inflammatory bowel condition, did not meet the main goal
in a late-stage study.
(Reporting by Mariam Sunny in Bengaluru)